that start proud pandemic. Thank and you your by I are unprecedented the hope very safe am how of in to Medical the healthy. and your great interest saying Care, of you, face me very Fresenius much families ongoing employees Care and allow Please of in I to Hello, efforts you It's with Dominik. sincerely I appreciate everyone. have us today. Fresenius Medical this
you receive environment become ensure dialysis the to high and their thank Please lifesaving very safe they've in Our more treatments much, FMC than XXX,XXX continue to. me, employees. quality that same allow with a accustomed our employees patients
with you You're live as three this virtually in as are hero. that in, has current we world In business what become locations. usual, in has pointed we Hang there. my Dominik out from
Let's start technology underlying holds as we the exchange Slide up two. the clouded business I'll real go good my remarks had In somewhat hope performance, on through unfavorable or by very we please. rates. our prepared quarter, next hour X,
in and resilience our quarter Our of model. proves the business the the third value proposition generation FMC core earnings strong
the the due months We have to the managed for to is but roughly headwind drive COVID-XX This States, be North effect development predominantly improvements partly we steady support, business first in this neutral to commercial due government that United to This our is mix. the also due an were year. to good of X continue despite we from the America, for. In to calcimimetics. continue efficiency able improved in
If new X-month world normal the new on figures, various pandemic impacts. pay, which the but at from knows outlook, is as accelerate this in time. and you to equipment, are are it cost et quarter The protective includes year long light cost the present support will our cover None COVID-XX targets treatment look Governmental anticipated of predictable. personal In continues us way or parts, our uncertain the for our our normal. around we will XXXX. back the reach anything in of see go and, to the cetera. to same XXXX. higher heroes how fourth confirming we our these additional time, goes for of you The into moving currently at feel the is normal We at that headwind volumes a
X. Slide to Turning
our services are grow, while and remaining steadfast quality. patients. consistently in to to we products quality high our We dialysis for of level commitment continue deliver very in We a
clinics just grow globally. XX treatments we XXX,XXX America clinic continuing service to clinics of to And home our seen provided to on than X% clinics, over we business, reducing are Although we expand million by in months our a more just over focus these our X with for North worldwide. are first patients growth XXXX. we X,XXX stronger In have the
Quality X. on priority our our the in the most care factor to and business patient is Turning important sustainability Slide top agenda.
committed to around We provide best possible are our the for outcomes globe. the patients
hospital regions. give further in during Here, of days the the you to like that our quarter. suspect patients questions I has hospitalized I'm have the focus happy pandemic, environment were spent Q&A, insight. would KPIs that that our to further the in Despite number days one have number I challenging may you most patients on down for the is the come of of of some the and the of in
Turning In income Including we for growth, X. to in very positive deliver continued significant third currency focused to management. strong of the operating quarter due part XXXX, performance to billion. the headwinds expense €X.X large and Slide of amounted stable the revenue to quarter and X%, foreign was
steady remain revenue effects, rate the result its negative products X% a despite saw business While headwinds. as these of FX decreased the Care exchange Services Health
Our Helen operating currency. presentation. some strength XX% and by to you insight during more And will income constant our operating have both increasing net we earnings with as in income deterred not was her at COVID-XX, normally do,
North a a each the of growth rate business, X%. from from calcimimetics in The Turning growth particularly the unfavorable ,despite services from treatments due contributed organic in regions. and in several Pacific further growth number Latin We figures. the an the A in increase in benefiting America. to exchange obviously, positive EMEA same had were and reported the stronger the to we largely COVID-XX. was Slide from supported America and countries treatment In in development. But the the market of headwind region other organic X. to Asia all sizable the in there and improved COVID-XX slower We organic mix organic payer saw this by to delivered driven America quarter, regions. developments X% growth of four of from contributions headwinds North growth organic calcimimetics X% effects despite growth
growth Despite quarter. performance growth countries North for Slide on COVID-XX were challenges Health of America Turning a several X% East prior organic Asia included basis, In a the some Services slower by Care increase by the number across year adjustments, drivers to Pacific, X% had we same mentioned. higher X. regions, Care solid reimbursement the in In time, Middle driven by of discuss Helen in portion showed commercial and the Africa, the and Coordination. and same for in Growth in from growth presented which for treatments revenue. same a services. calcimimetics, expected market in lower an to addition, will growth At of previously faced global was headwinds treatments; the and the treatments effects COVID-XX. These an due market the achieved same-store strong driven Europe, drag Asian as growth dialysis on we region and a later;
revenues currency XX, headwinds. were Slide Product impacted to products. by sizable Turning
Eastern postponed growth saw dialysis peritoneal an currency chronic the negative planned Products X% tenders treatments, QX machines products. dialysis EMEA in by East. organic for by QX areas been Dialysis in the Middle products headwinds, in for of can revenue overall driven of acute treatment sales for and into Excluding the higher increase Europe The of and explained that were that for products be care have
Product hand, On increased the to non-Dialysis XX% the million. €XX by revenue other
it As development and remarks, current concludes to turn This the of my it's the due prepared pleasure pandemic. quarter, Helen. in previous the to this my partly over to is